RBFOX1常见变异与早期及临床前阿尔茨海默病脑淀粉样变性的关联
该遗传关联研究基于6个多中心队列的4314名健康老年人,采用全基因组关联分析发现RBFOX1位点与脑淀粉样变性相关(β=0.61,P=3×10-9),并在独立队列中验证RBFOX1表达降低与淀粉样β负荷增高和认知功能下降相关。
要点
- RBFOX1是除APOE外与临床前阿尔茨海默病脑淀粉样变性相关的新位点。
- RBFOX1蛋白定位于斑块周围,其表达降低与淀粉样β负荷增高相关。
- RBFOX1表达降低与认知功能下降相关。
核心结论
- RBFOX1是可能参与阿尔茨海默病发病机制的新位点。
研究设计与样本
- 第一阶段对6个多中心队列的4314名参与者进行全基因组关联分析,使用淀粉样PET成像和DNA数据。
- 第二阶段使用宗教秩序研究和拉什记忆与衰老项目的病理和临床数据验证遗传发现。
主要发现
- 在4314名参与者中(年龄52-96岁;2478名女性[57%]),除APOE外,发现RBFOX1位点与淀粉样变性相关(β=0.61,P=3×10-9)。
- RBFOX1蛋白定位于斑块周围。
- 在宗教秩序研究和拉什记忆与衰老项目队列中,RBFOX1表达降低与生前更高的淀粉样β负荷相关(β=-0.008,P=.002)。
- RBFOX1表达降低与生前更差的认知功能相关(β=0.007,P=.006)。
临床怎么用
- RBFOX1可作为临床前阿尔茨海默病脑淀粉样变性的潜在遗传标志物进行进一步研究。
- RBFOX1表达水平可能有助于评估阿尔茨海默病病理负荷和认知功能下降风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Genetic studies of Alzheimer disease have focused on the clinical or pathologic diagnosis as the primary outcome, but little is known about the genetic basis of the preclinical phase of the disease. OBJECTIVE: To examine the underlying genetic basis for brain amyloidosis in the preclinical phase of Alzheimer disease. DESIGN, SETTING, AND PARTICIPANTS: In the first stage of this genetic association study, a meta-analysis was conducted using genetic and imaging data acquired from 6 multicenter cohort studies of healthy older individuals between 1994 and 2019: the Anti-Amyloid Treatment in Asymptomatic Alzheimer Disease Study, the Berkeley Aging Cohort Study, the Wisconsin Registry for Alzheimer's Prevention, the Biomarkers of Cognitive Decline Among Normal Individuals cohort, the Baltimore Longitudinal Study of Aging, and the Alzheimer Disease Neuroimaging Initiative, which included Alzheimer disease and mild cognitive impairment. The second stage was designed to validate genetic observations using pathologic and clinical data from the Religious Orders Study and Rush Memory and Aging Project. Participants older than 50 years with amyloid positron emission tomographic (PET) imaging data and DNA from the 6 cohorts were included. The largest cohort, the Anti-Amyloid Treatment in Asymptomatic Alzheimer Disease Study (n = 3154), was the PET screening cohort used for a secondary prevention trial designed to slow cognitive decline associated with brain amyloidosis. Six smaller, longitudinal cohort studies (n = 1160) provided additional amyloid PET imaging data with existing genetic data. The present study was conducted from March 29, 2019, to February 19, 2020. MAIN OUTCOMES AND MEASURES: A genome-wide association study of PET imaging amyloid levels. RESULTS: From the 4314 analyzed participants (age, 52-96 years; 2478 participants [57%] were women), a novel locus for amyloidosis was noted within RBFOX1 (β = 0.61, P = 3 × 10-9) in addition to APOE. The RBFOX1 protein localized around plaques, and reduced expression of RBFOX1 was correlated with higher amyloid-β burden (β = -0.008, P = .002) and worse cognition (β = 0.007, P = .006) during life in the Religious Orders Study and Rush Memory and Aging Project cohort. CONCLUSIONS AND RELEVANCE: RBFOX1 encodes a neuronal RNA-binding protein known to be expressed in neuronal tissues and may play a role in neuronal development. The findings of this study suggest that RBFOX1 is a novel locus that may be involved in the pathogenesis of Alzheimer disease.
引用
- Raghavan NS, Dumitrescu L, Mormino E, et al. Association Between Common Variants in RBFOX1, an RNA-Binding Protein, and Brain Amyloidosis in Early and Preclinical Alzheimer Disease. JAMA Neurol. 2020. PMID: 32568366. doi:10.1001/jamaneurol.2020.1760
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。